This week's episode of the Readout LOUD!
How do obesity biotechs compete against Novo Nordisk and Eli Lilly? Why does gene therapy pioneer Jim Wilson think there's "irrational pessimism" in the field? And why isn't Immunovant advancing the drug it just reported positive data on? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. We chat about positive data from Immunovant's autoimmune drug candidate, a patient death linked to Sarepta's gene therapy, and dispatches from our STAT Breakthrough Summit East in New York. We also bring on Zealand Pharma CEO Adam Steensberg to talk about his company's amylin-targeting obesity treatment, the partnership deal it recently signed with Roche, and his thoughts on the industry's intense focus on weight loss. Listen Now For more on Immunovant's new data, go here; for more on Sarepta's gene therapy, go here; to learn more about Zealand's deal with Roche, go here; and to read about the panels at our Breakthrough East Summit, go here. Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2025, All Rights Reserved. | |
|
No comments